Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| DiaMedica Therapeutics Inc | DMAC | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.85 | 03:16:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.85 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.9382 - 4.75 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 2.85 | USD |
DiaMedica Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 108.17M | 37.95M | - | 0 | -13.68M | -0.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
DiaMedica Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DMAC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.02 | 3.02 | 2.78 | 2.85 | 12,318 | -0.17 | -5.63% |
| 1 Month | 2.58 | 3.73 | 2.50 | 3.27 | 41,081 | 0.27 | 10.47% |
| 3 Months | 3.10 | 3.73 | 2.26 | 2.93 | 39,312 | -0.25 | -8.06% |
| 6 Months | 2.64 | 3.73 | 2.26 | 2.89 | 41,072 | 0.21 | 7.95% |
| 1 Year | 3.02 | 4.75 | 1.9382 | 3.20 | 75,254 | -0.17 | -5.63% |
| 3 Years | 7.54 | 9.55 | 1.12 | 3.29 | 106,960 | -4.69 | -62.20% |
| 5 Years | 2.81 | 10.88 | 1.12 | 4.38 | 101,405 | 0.04 | 1.42% |
DiaMedica Therapeutics Description
| DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1. |
